Jan 04, 2024 / 02:30PM GMT
Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division - VP
Thank you for joining us. And with Herve on stage is Matt Dellatorre, who's been following the story for a very long time. To start here, Herve, a big picture question. Product diversification continues to be a key focus for Incyte. And as we stand today with Jakafi and Opzelura, and the current pipeline, notably, where you do have some later-stage assets such as Povorcitinib and axatilimab or outlook for the business and growth in 2024 and longer term?
Questions and Answers:
Herve Hoppenot - Incyte Corporation - CEO & ChairmanGood. No. I mean to see you. I was hoping to be able to blame you for infecting everybody at JPM next week. But somebody will have to be blamed. So that will be funny. Okay. Speaking about Incyte. I mean that is '24 is obviously starting. So now we are more or less seeing what's going to happen in some of the big events. And the long term is where there are a lot of interesting perspective.
I must maybe step back for a 1/10 of a minute here to
Trustpilot
